-
Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results
-
Ultimovacs’ Chief Scientific Officer Gustav Gaudernack Receives Norwegian Tech Award’s Honorary Prize as an Outstanding Pioneer Against Cancer
-
Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma
-
Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to first quarter 2023 results webcast presentation
-
Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma
-
Ultimovacs ASA – Share Option Program
-
Ultimovacs ASA – Annual General Meeting held on 20 April 2023
